Stran 1 iz 17 rezultatov
FIELD OF THE INVENTION
The invention provides cyclohexylamine derivatives as N-Methyl-D-Aspartate (NMDA) antagonists, pharmacological compositions comprising the derivatives, and methods of treating diseases and disorders responsive to antagonism of NMDA receptors using the derivatives.
BACKGROUND
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention is related to 4-substituted piperidine analogs, including hydroxypiperidine and tetrahydropyridine analogs, as well as novel intermediates of the 4-substituted analogs. The analogs are selectively active as antagonists of
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention is related to 4-substituted piperidine analogs, including hydroxypiperidine and tetrahydropyridine analogs, as well as novel intermediates of the 4-substituted analogs. The analogs are selectively active as antagonists of
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention is related to 2-substituted piperidine analogs. The analogs are selectively active as antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes. The invention is also directed to the use of 2-substituted piperidine analogs as
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention is related to 2-substituted piperidine analogs. The analogs are selectively active as antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes. The invention is also directed to the use of 2-substituted piperidine analogs as
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention is related to 4-substituted piperidine analogs, including hydroxypiperidine and tetrahydropyridine analogs. The analogs are selectively active as antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes. The invention is also
FIELD OF INVENTION
The invention relates to piperidine derivatives as N-Methyl-D-Aspartate (NMDA) antagonists useful in the treatment of diseases and disorders responsive to antagonism of NMDA receptors.
BACKGROUND OF THE INVENTION
Many of the physiological and pathophysiological effects of the
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention is related to 2-substituted piperidine analogs. The analogs are selectively active as antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes. The invention is also directed to the use of 2-substituted piperidine analogs as
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention is related to 2-substituted piperidine analogs. The analogs are selectively active as antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes. The invention is also directed to the use of 2-substituted piperidine analogs as
FIELD OF THE INVENTION
This invention is related to branched chain amino acid-dependent amino transferase (BCAT) inhibitors. The invention is also directed to the use of BCAT inhibitors as neuro-protective agents for treating conditions such as stroke, cerebral ischemia, central nervous system
FIELD OF THE INVENTION
This invention is related to branched chain amino acid-dependent amino transferase (BCAT) inhibitors. The invention is also directed to the use of BCAT inhibitors as neuro-protective agents for treating conditions such as stroke, cerebral ischemia, central nervous system
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to aminoalkyl substituted 5,6,7,8-tetrahydro-9H-pyridino[2,3-b]indole and 5,6,7,8-tetrahydro-9H-pyrimidino[4,5-b]indole derivatives, pharmaceutical compositions containing such compounds and their use in treating
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to aminoalkyl substituted 5,6,7,8-tetrahydro-9H-pyridino[2,3-b]indole and 5,6,7,8-tetrahydro-9H-pyrimidino[4,5-b]indole derivatives, pharmaceutical compositions containing such compounds and their use in treating
FIELD OF THE INVENTION
The invention presented herein is directed to novel imidazopyrimidinyl and imidazopyridinyl derivatives, and to their use as CRF antagonists in the treatment of a variety of neurological and psychiatric disorders.
BACKGROUND OF THE INVENTION
Corticotropin releasing factor
BACKGROUND OF THE INVENTION
Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et